EpiVax participated in the  2021 International Society for Vaccines (ISV) Annual Virtual Congress September 13-15, 2021.

The 2021 Congress was a busy one, it’s been a difficult but innovative period for the vaccine development community.

Multiple EpiVax scientists presented throughout the three-day event, details below!

EpiVax Director of Vaccine Research, Dr. Lenny Moise,  co-chaired the Plenary Session 2 alongside Amy Epeseth from Merck.

Dr. Michael Princiotta, CSO of EpiVax Therapeutics, presented Efficient Selection of Tumor Associated neoantigens in the Design of Personal Vaccines”  during the first Plenary Session on Monday, September 13th. Watch the talk below!

The EpiVax Vaccine Team presented several posters during the  ISV Poster session. Check them out below!

“Highly conserved, non-human-like, and cross-reactive SARS-CoV-2 T cell epitopes for COVID-19 vaccine design and validation”.



“Novel Immunogen design elicits increased protection against avian H7N9 influenza that is associated with mobilization of seasonal influenza T cell memory.”


And to round out the event, ISV Fellow and EpiVax CEO/CSO Dr. Annie De Groot participated in the Meet the Fellows session on Wednesday, September 15th!